MedTrace Logo

Ambispective Cohort Study of Precision Medicine for Primary Hepatobiliary Cancer Based on Next-generation Sequencing

NCT05520788 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 200

Last updated 2025-02-11

No results posted yet for this study

Summary

Exploring the precise medicine of patients with primary hepatobiliary cancer. And evaluate the efficacy and safety of individualized treatment regimens for primary hepatobiliary cancer based on next-generation sequencing.

Conditions

Interventions

GENETIC

precise medicine

During screening stage, all patients should accept next-generation sequencing (NGS) test.

Sponsors & Collaborators

  • Tongji Hospital

    lead OTHER

Principal Investigators

  • Wanguang Zhang · Tongji Hospital

  • Zeyang Ding · Tongji Hospital

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-05-01
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05520788 on ClinicalTrials.gov